A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Progression-free survival
over the course of the study
No
Chandra Belani, M.D.
Study Chair
Milton S. Hershey Medical Center
United States: Food and Drug Administration
CYC202-06-14 (A1)
NCT00372073
July 2006
March 2012
Name | Location |
---|---|
Arizona Cancer Center | Tucson, Arizona 85724 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Southwest Regional Cancer Center | Austin, Texas 78705 |
Nevada Cancer Research Foundation | Las Vegas, Nevada 89109 |
Vanderbilt University Medical Center | Nashville, Tennessee 37232-2516 |
Center for Oncology Research and Treatment | Dallas, Texas 75230 |
New Mexico Oncology Hematology Consultants | Albuquerque, New Mexico 87102 |
Dana Farber Cancer Institute | Boston, Massachusetts 02115 |
Columbia Presbyterian Medical Center | New York, New York 10032 |
The University of Chicago | Chicago, Illinois 60637 |
The Family Cancer Center | Collierville, Tennessee 38017 |
VA Sierra Nevada Health Care System | Reno, Nevada 89502 |
Pasco Hernando Oncology | New Port Richey, Florida 34652 |
Penn State Milton S. Hershey Medical Center | Hershey, Pennsylvania 17033 |
Nebraska Medical Center | Omaha, Nebraska 68198 |
Pacific Coast Hematology Oncology Group | Fountain Valley, California 92708 |
University of Maryland, Greenebaun Cancer Center | Baltimore, Maryland 21201 |
University of Pittsburg Cancer Institute | Pittsburgh, Pennsylvania 15232 |
East Texas Medical Center | Tyler, Texas 75701 |
Danville Hematology Oncology | Danville, Virginia 24541 |